synthesis and immunologic characterisation of mycobacterium

CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update Synthesis and Immunologic Characterisation of Mycobacterium Hamasur, Beston; Kallenius, Gunilla; Svenson, Stefan B.
July 23, 1999

Vaccine Online (07/16/99) Vol. 17, No. 22, P. 2853 Swedish researchers synthesized and immunologically characterized immunogenic lipoarabinomannan (LAM)-specific oligosaccharide protein conjugates. The researchers derived the oligosaccharides from LAM purified from Mycobacterium tuberculosis H37 Rv and covalently conjugated to tetanus toxoid and cross-reactive mutant diphtheria toxoid. "Both types of LAM oligosaccharide protein conjugates proved to be highly immunogenic, inducing a boosterable T helper cell dependent IgG response," the authors report. Such conjugates are currently being assessed as components for an experimental subcellular TB vaccine.

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 Positive living Lawyer: NY man at center of HIV scare not positive Zimbabwe activist: Prisoners denied AIDS drugs Youth organizations form a pact for social transformation in the AIDS response CountyCare Offers Historic Opportunity to Improve Care for People with HIV International AIDS Advocates Demand China Give $1 Billion to Global Fund Kingdom of Bahrain and UNAIDS commit to intensify cooperation CANADA: Celibate Homosexual Men Now Allowed to Donate Blood in Canada AFRICA: UN: AIDS Deaths Down, Treatment Up in Africa MICHIGAN: STD Fee for Jackson County Walk-In Clinic Takes Effect June 3 FDA announced approval of Rifabutin, a drug to prevent Mycobacterium avium complex (MAC) disease in people with advanced HIV infection Opportunistic Infections & Other Complications: Mycobacterium Avium Complex (MAC) VIII International Conference on AIDS: Mycobacterium Avium Complex (MAC) (STEP) Recent Development In The Treatment And Prevention Of Disseminated Mycobacterium Avium Complex (MAC) (STEP) Recent Development In The Treatment And Prevention Of Disseminated Mycobacterium Avium Complex (MAC) Recommendations for Use of an Isoniazid-Rifapentine Regimen with Direct Observation to Treat Latent Mycobacterium tuberculosis Infection (BETA) Opportunistic Infections: Indoor Potted Plant Soil is a Source of Mycobacterium avium (BETA) Mycobacterium avium Complex Disease: Clinical Updates Human Papillomavirus: HIV Adversely Affects Synthesis of Th1 Cytokines in Women with Active HPV Infection AIDS Therapies: As Cell Count Increases, Treatment for Mycobacterium avium Not Needed
Copyright © 1999 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles. Information in this article was accurate in July 23, 1999. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.